Our Mission

Our goal is to identify novel putative cancer targets for drug discovery, diagnostic and/or prognostic applications. For this purpose, we use a high-throughput screening technology, tissue microarrays (TMAs), together with in situdetection methods, i.e., RNA in situhybridization (ISH) and immunohistochemistry (IHC), to translate early discoveries into clinical applications. TMA screening allows:

  • Validation of basic research findings through the rapid and simultaneous analysis of hundreds of patient samples.
  • Assessment of the prevalence of candidate gene deregulation through comparative expression analysis of normal tumor tissues.
  • Identification of candidate diagnostic and prognostic markers through the correlation of expression results with clinicopathological and follow-up data in patient cohorts.
  • Validation of druggable targets based on extensive in situanalysis in tumor samples.

Our Services

Human specimens:

  • Tissue processing, tissue sectioning, slide staining and in situanalyses (ISH, IHC, FISH, etc.).
  • Pathology material storage.
  • Generation of multi-tumor TMAs, sectioning and distribution.
  • Target validation.
  • Assistance with procedures and technical support.
  • Pathology expertise.
  • Clinical data correspondence.
  • Complete molecular reports with image collection and data interpretation.
  • Statistical analysis.
  • Clinicopathological and molecular databases.
  • Access to high density collections, case collections with extensive follow-up, and cancer-specific TMAs, on a collaborative basis.


Mouse specimens:

  • Maintenance and upkeep of space dedicated to mouse pathology and assistance to users.
  • Establishment of a pipeline from tissue to section.
  • Assistance with procedures and technical support (mostly IHC and ISH).
  • Mouse registry (centralization and automation of data, storage, retrieval).
  • Mouse pathology expertise.

Our site uses cookies for better browsing usability and statistics on its use. If you want to learn more, or refuse consent to all or some cookies, click here.